^
    Back
    Association details:
    Biomarker:EML4-ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

    Excerpt:
    ......
    Trial ID:
    NCT00932893
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Thorac Cancer
    Title:

    Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial

    Published date:
    01/20/2021
    Excerpt:
    CONTRACDICTING EVIDENCE: Patients with ALK-rearranged tumors treated with alectinib immediately before enrolling in the trial received crizotinib monotherapy....The overall response rate was 33.3%...The median survival time was 24.1 months...crizotinib monotherapy following treatment with alectinib showed efficacy alongside previously described adverse events.
    DOI:
    10.1111/1759-7714.13825
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Immunotherapy
    Title:

    Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer

    Published date:
    05/31/2023
    Excerpt:
    Here, a stage IIIB NSCLC patient with EML4-ALK fusion mutation receiving immunotherapy plus chemotherapy as neoadjuvant treatment followed by lobectomy plus lymph node dissection is reported. The patient achieved a pathological complete response according to pathological evaluation. The patient received adjuvant crizotinib for 3 months and achieved a disease-free survival time of 36 months.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.2217/imt-2022-0302
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    PLoS One
    Title:

    Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing

    Excerpt:
    In patient #1, we confirmed the presence of the EML4-ALK fusion gene in the post-treatment sample taken from a tumor growing under crizotinib.
    DOI:
    10.1371/journal.pone.0153065
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    NEJM
    Title:

    EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

    Excerpt:
    In a case of EML4-ALK–positive non–small-cell lung cancer that became resistant to crizotinib after successful treatment for 5 months…
    DOI:
    10.1056/NEJMoa1007478